Last mentioned: Mar 20, 2026
Profitability Target
Antengene aims to achieve its first full year of profitability.
AACR 2026
Antengene scheduled to present data on next-generation ADCs and TCEs.
Clinical Filings Target
Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.
2025 FY Results
Company announces full-year results and confirms shift toward 2026 profitability.
Investor Briefings
Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.
Investor Briefings
Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.
UCB Partnership
Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.
Global License Agreement
Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.
Global License Agreement
Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.
Regulatory Filings
Planned submission of clinical trial applications for ATG-201 in China and Australia.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform.